Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases $24,750.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel purchased 1,800 shares of the business's stock in a transaction that occurred on Tuesday, January 7th. The stock was bought at an average cost of $13.75 per share, with a total value of $24,750.00. Following the acquisition, the chief executive officer now owns 5,550,002 shares of the company's stock, valued at approximately $76,312,527.50. The trade was a 0.03 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Snehal Patel also recently made the following trade(s):

• On Thursday, January 2nd, Snehal Patel purchased 2,000 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $11.97 per share, for a total transaction of $23,940.00.
• On Monday, December 30th, Snehal Patel acquired 3,200 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $11.12 per share, with a total value of $35,584.00.

Greenwich LifeSciences Stock Down 3.3 %

NASDAQ:GLSI traded down $0.46 on Wednesday, hitting $13.35. The stock had a trading volume of 34,049 shares, compared to its average volume of 46,430. The company has a fifty day moving average price of $13.18 and a two-hundred day moving average price of $14.14. Greenwich LifeSciences, Inc. has a 1-year low of $8.00 and a 1-year high of $21.44. The stock has a market cap of $175.49 million, a price-to-earnings ratio of -16.69 and a beta of 1.66.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its stake in shares of Greenwich LifeSciences by 4.6% in the 3rd quarter. Geode Capital Management LLC now owns 133,550 shares of the company's stock valued at $1,919,000 after purchasing an additional 5,861 shares during the last quarter. State Street Corp lifted its position in Greenwich LifeSciences by 4.4% in the third quarter. State Street Corp now owns 71,408 shares of the company's stock valued at $1,026,000 after buying an additional 3,005 shares during the last quarter. Garden State Investment Advisory Services LLC purchased a new position in Greenwich LifeSciences during the third quarter worth about $253,000. Bank of New York Mellon Corp purchased a new position in Greenwich LifeSciences during the second quarter worth about $264,000. Finally, Barclays PLC increased its position in shares of Greenwich LifeSciences by 323.3% during the third quarter. Barclays PLC now owns 8,560 shares of the company's stock valued at $123,000 after acquiring an additional 6,538 shares during the last quarter. 4.16% of the stock is currently owned by hedge funds and other institutional investors.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.